I-Mab IMAB

NAS: IMAB | ISIN: US44975P1030   14/11/2024
1,070 USD (+2,88%)
(+2,88%)   14/11/2024

10 september 2024 · I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer · Persbericht

28 augustus 2024 · I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates · Persbericht

26 augustus 2024 · I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

14 augustus 2024 · I-Mab to Release 1H 2024 Financial Results on August 28, 2024 · Persbericht

7 augustus 2024 · I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) · Persbericht

15 juli 2024 · I-Mab Announces Leadership Transitions · Persbericht

6 juni 2024 · I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer · Persbericht

5 juni 2024 · I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers · Persbericht

22 mei 2024 · I-Mab to Participate at the Jefferies Global Healthcare Conference · Persbericht

30 april 2024 · I-MAB Filed 2023 Annual Report on Form 20-F · Persbericht

5 april 2024 · I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

2 april 2024 · I-Mab Announces Closing of the Divestiture of Business Operations in China · Persbericht

14 maart 2024 · I-Mab Reports Full Year 2023 Financial Results and Business Update · Persbericht

7 februari 2024 · I-Mab Signs Agreement to Divest its Assets and Business Operations in China · Persbericht

6 november 2023 · I-Mab Announces Participation at Jefferies and Piper Conferences in November · Persbericht

2 november 2023 · Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) · Persbericht

1 november 2023 · I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 · Persbericht

16 oktober 2023 · I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 · Persbericht

10 oktober 2023 · I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 · Persbericht

4 oktober 2023 · Thinking about buying stock in ALX Oncology Holdings, RedHill Biopharma, Freeline Therapeutics Holdings, Terawulf, or I-Mab? · Persbericht

Mijn selecties